Posted by Michael Wonder on 15 Jun 2022
Effective biomedical public-private partnerships are about innovation, not lower drug prices
15 June 2022 - There is fascination of late with the prospect of exercising Bayh-Dole Act “march-in rights,” primarily as a means of reducing the price of expensive drugs that have been discovered or developed with federal funds.
In recently published pieces in Health Affairs Forefront and elsewhere, some contend that the intended public health benefits of biomedical public-private partnerships will be realised only if the drug prices paid by consumers are reduced prior to patent expiry.
